![conference banner](/images/conference-banner.jpeg)
Abstract
Radiopharmaceuticals can provide unique information for drug development also in cardiovascular applications. Radiopharmaceuticals offer possibility to study noninvasively cardiac perfusion, oxygen consumption, oxidative and substrate metabolism, myocardial efficiency of work, neural actions and receptors, vascular inflammation, and molecular processes which all are relevant to understand the effects of drugs. Using these surrogate end points, hypotheses can be tested in vivo in phase I and II clinical studies before starting large-scale clinical phase III or IV trials. In addition, these approaches may allow improved selection of drug therapy for a given patient. Modern techniques such as gene therapy technology provide numerous new potential mechanisms of action and targets for drug development. Device therapies and cell therapies are also under rapid development. Molecular imaging has great potential in evaluating these new therapies and selecting the patient populations and monitoring of the effect of therapy.
Keywords: Cardiovascular Drug, Radiopharmaceuticals, vascular inflammation, CARDIAC PERFUSION, METABOLISM, Molecular imaging
Current Pharmaceutical Design
Title: Cardiovascular Drug Development Using Radiopharmaceuticals
Volume: 15 Issue: 9
Author(s): Heikki Ukkonen, Keiichiro Yoshinaga, Jean N. DaSilva, Rob S.B. Beanlands and Juhani Knuuti
Affiliation:
Keywords: Cardiovascular Drug, Radiopharmaceuticals, vascular inflammation, CARDIAC PERFUSION, METABOLISM, Molecular imaging
Abstract: Radiopharmaceuticals can provide unique information for drug development also in cardiovascular applications. Radiopharmaceuticals offer possibility to study noninvasively cardiac perfusion, oxygen consumption, oxidative and substrate metabolism, myocardial efficiency of work, neural actions and receptors, vascular inflammation, and molecular processes which all are relevant to understand the effects of drugs. Using these surrogate end points, hypotheses can be tested in vivo in phase I and II clinical studies before starting large-scale clinical phase III or IV trials. In addition, these approaches may allow improved selection of drug therapy for a given patient. Modern techniques such as gene therapy technology provide numerous new potential mechanisms of action and targets for drug development. Device therapies and cell therapies are also under rapid development. Molecular imaging has great potential in evaluating these new therapies and selecting the patient populations and monitoring of the effect of therapy.
Export Options
About this article
Cite this article as:
Ukkonen Heikki, Yoshinaga Keiichiro, DaSilva N. Jean, Beanlands S.B. Rob and Knuuti Juhani, Cardiovascular Drug Development Using Radiopharmaceuticals, Current Pharmaceutical Design 2009; 15 (9) . https://dx.doi.org/10.2174/138161209787582011
DOI https://dx.doi.org/10.2174/138161209787582011 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Fathoming the Role of mTOR in Diabetes Mellitus and its Complications
Current Molecular Pharmacology Cytochrome P450 and the Biological Clock in Mammals
Current Drug Metabolism Nanocarriers in the Delivery of Hydroxychloroquine to the Respiratory System: An Alternative to COVID-19
Current Drug Delivery Postoperative Atrial Fibrillation - What Do We Really Know?
Current Vascular Pharmacology ADAM17 as a Therapeutic Target in Multiple Diseases
Current Pharmaceutical Design Amniotic Fluid Embolism: Moving Diagnosis Through the Time. From the Mechanical Pulmonary Vascular Occlusion Until An Immuno - Inflammatory Pathogenesis?
Current Pharmaceutical Biotechnology Molecular Basis of Antiretroviral Drugs-Associated Long-Term Toxicity: How Bad can Good Drugs Be?
Current Medicinal Chemistry - Anti-Infective Agents Signal Transduction Inhibitors in the Treatment of Breast Cancer
Current Medicinal Chemistry - Anti-Cancer Agents Telmisartan in the Management of Diabetic Nephropathy: A Contemporary View
Current Diabetes Reviews Hyperpolarized Metabolic MR in the Study of Cardiac Function and Disease
Current Pharmaceutical Design The Role of microRNA-126 in Vascular Homeostasis
Current Vascular Pharmacology Biological Active Ingredients of Traditional Chinese Herb Astragalus membranaceus on Treatment of Diabetes: A Systematic Review
Mini-Reviews in Medicinal Chemistry Cardiac Protection via Metabolic Modulation: An Emerging Role for Incretin-Based Therapies?
Cardiovascular & Hematological Agents in Medicinal Chemistry Diabetes and Chronic Heart Failure: From Diabetic Cardiomyopathy to Therapeutic Approach
Endocrine, Metabolic & Immune Disorders - Drug Targets Autophagy as a Molecular Target of Flavonoids Underlying their Protective Effects in Human Disease
Current Medicinal Chemistry Clinical Applications and Biosafety of Human Adult Mesenchymal Stem Cells
Current Pharmaceutical Design Effectiveness of Resveratrol Against Cardiovascular Disease
Mini-Reviews in Organic Chemistry Therapeutic Potential of Caffeic Acid Phenethyl Ester (CAPE) in Diabetes
Current Medicinal Chemistry The Two fACEs of the Tissue Renin-Angiotensin Systems: Implication in Cardiovascular Diseases
Current Pharmaceutical Design Autophagy in Chronic Myeloid Leukaemia: Stem Cell Survival and Implication in Therapy
Current Cancer Drug Targets